- Monovalent
- Polyvalent
Antivenom Market size was valued at USD 2.48 billion in 2022 and is poised to grow at a CAGR of 5.9% from 2023-2029. Antivenom is also called as antivenin. Antivenom is a medication prepared from antibodies that are used to treat certain venomous bites. Poisonous bites result in certain clinical conditions such as muscle weakness, secretion of excessive saliva, breathing problems, along with other difficulties, in some instances that might lead to death as well. Antivenins are recommended only if there is significant toxicity or a high risk of toxicity. Antivenom is made by collecting venom from the relevant venomous species of spider, snake, fish, injecting venom in little amounts to domestic animals and antibodies are separated from blood purification. These antibodies are used as antivenom. Growing demand of antivenom worldwide, especially in Africa and the Asia-Pacific region owing to more number of venomous bite incidents. According to World Health Organization (WHO), about 5 Mn snake bites occur each year, resulting 2.5 Mn envenomings (poisoning because of snake bites), minimum 100,000 deaths and around three times as many amputations and other permanent disabilities. Withdrawal of antivenoms like Fav-Afrique by Pfizer further grew demand for the market. Market players are also actively involved in R&D to develop antivenoms and to enhance their market position. In addition, many market players and institutions are actively involved in the development of new antivenoms. For instance, Equine F (ab') 2 in antivenin is being developed by Instituto Bioclon S.A (clinical trials phase 2) for the treatment of poisoning by a scorpion sting. Based on the aforementioned factors market is expected to grow with a significant CAGR rate during the forecast period. Polyvalent anti-venoms are antibodies that can neutralize a variety of homologous venoms from different species/genera. In most circumstances and roughly 80% of the time when a monovalent antivenom cannot be chosen, polyvalent antivenoms can save the lives of snake envenomation victims, even when the perpetrator snake is unknown. Polyvalent anti-venoms are the most recommended anti-venom medication due to their evident advantages. Because of the current COVID-19 situation, all firms' research and development resources are being diverted to COVID-19 research, and there has been little or no research in this category in recent years, which will have an impact on market growth.
Global Antivenom Market Summary
Study Period
2023-29
Base Year
2022
CAGR
5.9%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Antivenom Market Dynamics
Increase in government initiatives to develop antivenoms and incidents of the venomous bites in undeveloped regions are fueling the growth of market over the forecast period. In addition, rise in deaths due to venomous bites and technological advancements in the development of antivenom creates significant opportunities for the antivenom manufacturers. However, complexity in regulatory procedures, insufficient funding in development of antivenom, and high cost of the product are hindering growth.
Antivenom Market Regional Analysis
North America Got Significant Share
Geographically market is segmented into following regions viz. North America, Asia-Pacific, Latin America, Europe, and Middle East & Africa. North America contributes a major share in market due to the establishment of snake poison control centres, increase in antivenom products approval, rise in number of antivenom clinical trial conducting firms and presence of established health care facilities. Asia Pacific anti venom market is expected to have lucrative market growth owing to increase in number of snake bite cases as compared to developed regions. Furthermore, development of antivenom products for several species of snakes, rising demand for antivenom products, and increase in a number of local antivenom manufacturers such as Bharath Serum, Vaccines Limited and Vins Bioproducts focusing on antivenom products in the Asia region. In the case of the Middle East and Africa region, South Africa expected to have significant growth opportunity due to the highest number of snake bites in the country. Many of the global players are expected to expand their business to African market during the forecast period.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Global Antivenom Market Segmentation
By Product Type
By Animal
- Snake
- Scorpions
- Spiders
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
Frequently Asked Questions
The global antivenom market size was valued at USD 2.48 billion in 2022
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
BTG Plc (U.K), Bharat Serum and Vaccines Limited (India), CSL Limited (Victoria), Vins Bioproducts Limited (India), Rare Disease Therapeutics, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Instituto Bioclon, S.A. de C.V.(Mexico), Incepta Vaccine Ltd. (Bangladesh), Merck & Co., Inc. (U.S), Pfizer Inc. (U.S.)
- Executive summary
- Global Antivenom Market Introduction
- Global Antivenom Market ? Taxonomy
- Global Antivenom Market?Definitions
- Antivenom Type
- Reptile Type
- Immunoglobulin Type
- Distribution Channel
- Region
- Global Antivenom Market Dynamics
- Drivers
- Restraints
- Opportunities/Unmet Needs of the Market
- Trends
- Global Antivenom Market Dynamics ? Factors Impact Analysis
- Global Antivenom Market Dynamics ? Regulations
- US
- Europe
- Japan
- China
- Global Antivenom Market? Product Innovations
- Price Analysis
- Technological Landscape
- Value Chain Analysis
- Competitor Landscape
- Recent Flexible e-paper Product Launches
- Funds raised by the Start-ups
- Collaborations and acquisitions in market
- Global Antivenom Market Analysis 2017 ? 2025
- Market Analysis and Forecast, 2017 ? 2025 (Revenue, USD Mn)
- Year-over-Year (Y-o-Y) Growth Analysis (%)
- Market Opportunity Analysis
- Global Antivenom Market, By Antivenom Type, 2018 - 2024
- Monovalent
- Market Analysis and Forecast, 2017 ? 2025 (Revenue, USD Mn)
- Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- Market Opportunity Analysis
- Bivalent
- Market Analysis and Forecast, 2017 ? 2025 (Revenue, USD Mn)
- Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- Market Opportunity Analysis
- Trivalent
- Market Analysis and Forecast, 2017 ? 2025 (Revenue, USD Mn)
- Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- Market Opportunity Analysis
- Tetravalent
- Market Analysis and Forecast, 2017 ? 2025 (Revenue, USD Mn)
- Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- Market Opportunity Analysis
- Polyvalent
- Market Analysis and Forecast, 2017 ? 2025 (Revenue, USD Mn)
- Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- Market Opportunity Analysis
- Monovalent
- Global Antivenom Market , By Reptile Type, 2018 - 2024
- Snakes
- Market Analysis and Forecast, 2017 ? 2025 (Revenue, USD Mn)
- Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- Snakes
- 2.3. Market Opportunity Analysis
- Scorpions
- Market Analysis and Forecast, 2017 ? 2025 (Revenue, USD Mn)
- Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- Market Opportunity Analysis
- Others
- Market Analysis and Forecast, 2017 ? 2025 (Revenue, USD Mn)
- Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- Scorpions
- 2.3. Market Opportunity Analysis
- Global Antivenom Market Forecast, By Immunoglobulin Type, 2018 - 2024
- Homologous
- Market Analysis and Forecast, 2017 ? 2025 (Revenue, USD Mn)
- Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- Market Opportunity Analysis
- Heterologus
- Market Analysis and Forecast, 2017 ? 2025 (Revenue, USD Mn)
- Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- Market Opportunity Analysis
- Homologous
- Global Antivenom Market Forecast, By Distribution channel, 2018 - 2024
- Hospital Pharmacies
- Market Analysis and Forecast, 2017 ? 2025 (Revenue, USD Mn)
- Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- Market Opportunity Analysis
- Retail Pharmacies
- Market Analysis and Forecast, 2017 ? 2025 (Revenue, USD Mn)
- Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- Market Opportunity Analysis
- Hospital Pharmacies
- Global Antivenom Market Forecast, By Region, 2018 - 2024
- North America
- Market Analysis and Forecast, 2017 ? 2025 (Revenue, USD Mn)
- Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- Market Opportunity Analysis
- Europe
- Market Analysis and Forecast, 2017 ? 2025 (Revenue, USD Mn)
- Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- Market Opportunity Analysis
- Asia-Pacific
- Market Analysis and Forecast, 2017 ? 2025 (Revenue, USD Mn)
- Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- Market Opportunity Analysis
- Latin America
- Market Analysis and Forecast, 2017 ? 2025 (Revenue, USD Mn)
- Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- Market Opportunity Analysis
- Middle East & Africa
- Market Analysis and Forecast, 2017 ? 2025 (Revenue, USD Mn)
- Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- Market Opportunity Analysis
- Global Antivenom Market - Opportunity Analysis Index, By Antivenom Type,
- North America
Reptile Type, Immunoglobulin Type, Distribution Channel and Region, 2017 ? 2025
- North America Antivenom Market Analysis 2018 - 2024
- Antivenom Type Analysis Forecast (2017 ? 2025) by Revenue (USD Mn), Y-o-Y
Growth (%), and Market Share (%)
- Monovalent
- Bivalent
- Trivalent
- Tetravalent
- Polyvalent
- Reptile Type Analysis Forecast (2017 ? 2025) by Revenue (USD Mn), Y-o-Y Growth (%),
and Market Share (%)
- Snakes
- Scorpions
- Others
- Immunoglobulin Type Analysis Forecast (2017 ? 2025) by Revenue (USD Mn), Y-o-Y
Growth (%), and Market Share (%)
- Homologous
- Heterologous
12.1.4.Distribution Channel Analysis Forecast (2017 ? 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 12.1.4.1. Hospital Pharmacies 12.1.4.2. Retail Pharmacies 12.1.4.5. Others 12.1.5Country Analysis Forecast (2017 ? 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 10.1.5.1. U.S 10.1.5.2. Canada
- North America Antivenom Market - Opportunity Analysis Index, By Antivenom Type,
Reptile Type, Immunoglobulin Type, Distribution Channel, and Country, 2017 ? 2025
- North America Antivenom Market Dynamics - Trends
Europe Antivenom Market Analysis 2018 - 2024 11.1.1.Antivenom Type Analysis Forecast (2017 ? 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
- Monovalent
- Bivalent
- Trivalent
- Tetravalent
- Polyvalent
11.1.2.Reptile Type Analysis Forecast (2017 ? 2025) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 11.1.2 Snakes 11.1.2.1. Scorpions 11.1.2.2. Others 11.1.3.Immunoglobulin Type Analysis Forecast (2017 ? 2025) by Revenue (USD Mn), -o-Y Growth (%), and Market Share (%) 11.1.3.1. Homologous 11.1.3.2. Heterologus 11.1.4.Distribution Channel Analysis Forecast (2017 ? 2025) by Revenue
- Vins Bioproducts Limited (India)
- Bharat Serum and Vaccines Limited (India)
- CSL Limited (Victoria), Rare Disease Therapeutics, Inc. (U.S.)
- F. Hoffmann-La Roche AG (Switzerland)
- Instituto Bioclon, S.A. de C.V.(Mexico)
- Incepta Vaccine Ltd. (Bangladesh)
- BTG Plc (U.K)
- Merck & Co., Inc. (U.S)
- Pfizer Inc. (U.S.)